Verdict No. 1884 · Search date 2026-07-24 · Methodology v0.6
Septoplasty,
does it really help with Improved patient-reported symptoms and quality of life in nasal obstruction caused by a deviated septum?
30-Second Summary
C
Evidence Grade C · 58 · Safety caution
Septoplasty meaningfully improves at least moderate nasal obstruction from septal deviation versus medical management
Bleeding, infection, septal perforation, adhesions, altered smell, persistent obstruction, and revision surgery can occur. The 2025 meta-analysis reported bleeding and infection rates of about 4.12% each and revision of about 0.31%.
What the
research showsSeptoplasty earns C with 58 points despite a large symptom benefit because two design flaws impose a ceiling. Of 378 randomized participants, 307 entered the six-month primary analysis; SNOT-22 was 19.9 versus 39.5, adjusted difference -20.0 points (95% CI -23.6 to -16.4), P<0.001.
research showsSeptoplasty earns C with 58 points despite a large symptom benefit because two design flaws impose a ceiling. Of 378 randomized participants, 307 entered the six-month primary analysis; SNOT-22 was 19.9 versus 39.5, adjusted difference -20.0 points (95% CI -23.6 to -16.4), P<0.001.
What the
ads claimSurgery does not guarantee immediate elimination of every blockage or improvement in objective airflow. The meta-analysis found no clear PNIF difference.
ads claimSurgery does not guarantee immediate elimination of every blockage or improvement in objective airflow. The meta-analysis found no clear PNIF difference.
Useful facts when choosing a product
- Of 378 randomized participants, 307 entered the six-month primary analysis, an 18.8% attrition rate.
- The open-label comparison used patient-reported SNOT-22 as its primary outcome.
- The nine-point threshold was borrowed from another surgical population, not validated specifically for septoplasty.
Gap Measurement · Verdict 1884 · C 58
What the research actually shows
Across 17 NHS sites, 378 participants were randomized to surgery, 188, or medical management, 190; the six-month analysis included 152 and 155. SNOT-22 was 19.9 versus 39.5, adjusted difference -20.0 points (95% CI -23.6 to -16.4), P<0.001. The nine-point threshold was not validated for septoplasty but borrowed by rounding an 8.9-point value from another surgical population.
Why this is classified as C (58)
Large symptom improvement and replication are limited by 18.8% attrition and an unblinded patient-reported primary outcome, imposing C with 58 points.
Counterpoint. Bleeding, infection, septal perforation, and persistent symptoms remain possible.
Rejudgment record. Cross-check applied — Large patient-reported benefit with a ceiling imposed for 18.8% attrition and an unblinded self-rated outcome
Scoring profile behind this grade
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R2 | Independently replicated across trials |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved nasal symptoms at six months | B | The adjusted difference exceeded the nine-point threshold. |
| Improved nasal symptoms at twelve months | B | The effect was replicated in a three-trial meta-analysis. |
| Improved sinonasal quality of life | B | Patient-reported outcomes and SF-36 improved in NAIROS. |
Cross-check — Codex and Claude
This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Carrie S et al. 2023 (NAIROS) | Seventeen-center open-label randomized active-control trial | 1 | Public funding from the United Kingdom NIHR Efficacy and Mechanism Evaluation program | Primary six-month SNOT-22 outcome | Adjusted difference -20.0 points (95% CI -23.6 to -16.4), P<0.001; exceeded the nine-point benchmark borrowed from another surgical population | Key publicly funded confirmatory trial |
| Taha HI et al. 2025 | Systematic review and meta-analysis of randomized trials | 721 | No external study funding reported; no conflicts declared | NOSE, SNOT-22, and nasal airflow | Symptom benefit replicated at six and twelve months; no clear difference at three months or in PNIF | Multiple-trial replication |
| Hopkins C et al. 2009 | Prospective cohort validation of an outcome instrument | 3,128 | Academic data from a United Kingdom NHS national comparative audit | SNOT-22 minimally important difference derived in another surgical population | Minimal important difference was 8.9 points | Source of the borrowed benchmark |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-24).
Carrie S, O'Hara J, Fouweather T, et al. Clinical effectiveness of septoplasty versus medical management for nasal airways obstruction: multicentre, open label, randomised controlled trial. BMJ. 2023;383:e075445. PMID: 37852641. DOI: 10.1136/bmj-2023-075445.
checkedTaha HI, Elgendy MS, Ezz MR, et al. Septoplasty versus non-surgical management for deviated nasal septum: a systematic review and meta-analysis of randomized controlled trials. Eur Arch Otorhinolaryngol. 2025;282(2):597-610. PMID: 39230606. DOI: 10.1007/s00405-024-08937-x.
checkedHopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34(5):447-454. PMID: 19793277. DOI: 10.1111/j.1749-4486.2009.01995.x.
checkedDraft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Septoplasty x nasal obstruction from a deviated septum — Evidence Grade C·58. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/general/septoplasty-deviated-septum-nasal-obstruction/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.